BMCS Releases Limited 2015 Financial Information
Highlights include Gross Revenue up 45% over 2014; however half of that increase was due to receipt of a 2014 insurance claim received in 2015. BMCS had a loss of $456,055 for the year but closed its books with $3,376,272 in total assets. BMCS has no preferred shareholder debt.
BMCS Announces Move to Coppell, Texas BioTech Laser Center
BioTech Laser centers use FDA cleared non-surgical high powered deep penetrating Class III or Class IV LiteCure® lasers. We do not use "cold lasers". Over 92 ailments relating to muscle, nerve, skeletal and arthritic pain can be effectively treated with the LiteCure® Laser utilizing the proprietary BioTech Protocols. BioTech treats carpal tunnel syndrome, back and neck pain, Tennis Elbow, fiber myalgia and much more with a 90% success rate in reducing or eliminating debilitating pain without drugs or adverse side effects.
BMCS to Develop Anti-Zika Virus Products
On 2 February, the Centers for Disease Control and Prevention (CDC) officially declared that the Zika virus has been transmitted through sexual contact in Dallas, Texas. The virus is usually transmitted by the Aedes mosquito, but scientists discovered the Zika virus can be passed through sexual contact.